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Empirical Evidence of an Association Between Internal
Validity and Effect Size in Randomized Controlled
Trials of Low-Back Pain
Maurits W. van Tulder, PhD,*† Marika Suttorp, MSc,‡ Sally Morton, PhD,§
Lex M. Bouter, PhD,† and Paul Shekelle, MD, PhD‡¶
Study Design. We conducted a methodologic study.
Objective. The objective of this study was to assess
the validity of the criteria list recommended by the Co-
chrane Back Review Group Editorial Board by evaluating
whether individual items and a total score are associated
with effect sizes in randomized controlled trials of back-
pain interventions.
Summary of Background Data. There is concern that
studies of low methodologic quality may exaggerate the
effectiveness of treatments for low back pain. We per-
formed this study to examine the association between a
common measure of internal validity and the reported
magnitude of treatment effects.
Methods. We assessed the relationship between the
11 items contained in the Cochrane Back Review Group
Internal Validity checklist and effect size in randomized
trials of interventions for back pain. Of 267 trials in 15
Cochrane reviews that were eligible for inclusion, 51 were
excluded, leaving 216 trials included in the analysis. The
scores on the 11 items for each trial were taken from the
original review. We extracted effect sizes from each low
back pain trial.
Results. We found that trials that fulfilled a specific
item had smaller effect sizes compared with trials that did
not fulfill that item for 10 of the 11 items, and for 6 of the
criteria, the absolute difference in effect sizes was 0.10 or
greater. The 95% confidence interval of the difference in
effect sizes crossed the null value in each case. The num-
ber of items fulfilled showed that trials with higher
scores consistently reported smaller effect sizes than
trials with lower scores. At the thresholds of 5 or 6 items
fulfilled, the difference in effect sizes was 0.20 in each case
(95% confidence intervals 0.05–0.35 and 0.06–0.34, re-
spectively). Stratified analyses did not support confound-
ing by intervention.
Conclusion. We conclude that the 11-item Internal Va-
lidity Checklist is associated with effect size in randomized
trials of interventions for back pain, and that our data
support the use of a sum score of the number of fulfilled
items in this list.
Key words: Cochrane collaboration, randomized trials,
low back pain, bias, effect size. Spine 2009;34:1685–1692
There is concern that studies of low methodologic qual-
ity may exaggerate the effectiveness of treatments for low
back pain. We performed this study to examine the as-
sociation between a common measure of internal validity
and the reported magnitude of treatment effects. The
measurement of the internal validity of randomized con-
trolled trials (RCTs) is a key component of assessing the
evidence about health care interventions. How to mea-
sure internal validity remains controversial. Some studies
have reported empirical evidence relating to bias in
RCTs with some individual criteria such as concealment
of treatment allocation and blinding of patients,1,2 but
others have reported no significant association between
individual criteria and estimates of treatment effect.3
Further compounding the problem is the difficulty in
summarizing the assessment of the internal validity of an
RCT when the trial varies in its compliance with individ-
ual criteria. Jadad et al4 proposed and psychometrically
evaluated a scale to distinguish between trials with
“high” and “low” internal validity, which used 3 items:
randomization, double-blinding, and a description of
dropouts and withdrawals. Moher et al reported that
there was evidence to support the relationship between
risk of bias and effect size,5 and the Jadad scale has be-
come widely used as a summary measure of quality of
RCTs included in systematic reviews and meta-analyses.
However, as this scale was developed to assess drug trials
and double-blinding accounts for 40% of the score, the
Jadad scale is less useful for interventions where double-
blinding may be difficult. Furthermore, there is evidence
of a relationship with quality for criteria not included in
this scale (such as concealment of random allocation).1,2
Almost simultaneously with the development of the
Jadad scale, Verhagen et al developed a list of 9 items
focused specifically on internal validity. They used a for-
mal Delphi process of 3 rounds, with input from leading
experts around the world.6 Jadad et al and Verhagen et al
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developed their criteria lists in fields other than back pain
and it was unclear whether these lists were also valid for
back-pain studies.
Koes et al published the first systematic reviews in the
field of back pain in 1991.7,8 The assessment of the meth-
odologic quality of RCTs included in these reviews was
done using a list of criteria that was based on generally
accepted principles of intervention research, from text-
books on clinical epidemiology. This list included items re-
lated to internal validity, external validity, and precision.
Since that time, the potential hazards of using scales
were reported by Juni et al, who applied 25 different
published scales to 17 trials of low molecular weight
heparin. Depending on which scale was used to classify
trials as having high or low internal validity, the conclu-
sions of the review could be completely reversed. 9 Juni et
al postulated that their results were due in part to the
inclusion in most scales of items unrelated to internal
validity, such as items about ethics or external validity.
In 1997, the Cochrane Back Review Group (CBRG)
Editorial Board published method guidelines for system-
atic reviews in the field of spinal disorders, which they
updated in 2003.10 They recommended that 11 criteria
be used as the standard measure to assess the method-
ologic quality, or internal validity, of RCTs.11 This list
was based on the criteria in Jadad et al’s4 and Verhagen
et al’s lists6 and was a modification of the list used by
Koes et al.7,8 These criteria were used in 77% of the
CBRG reviews published in The Cochrane Library 2005,
issue 3. Furthermore, the CBRG Editorial Board recom-
mended using a score as a measure of overall internal
validity.8 Compliance with 6 criteria, resulting in a score
of 6, (similar to the threshold used in the Jadad scale of
about half the items being successfully met) was sug-
gested as a means of distinguishing high from low quality
trials.
The objective of this study was to assess the validity of
the criteria list recommended by the CBRG Editorial
Board by evaluating whether individual items and a total




Eligible Reviews. All CBRG reviews of a nonsurgical treat-
ment for nonspecific low back pain that were present in the
Cochrane Library 2005, issue 3, were eligible for inclusion.
Eligible Trials. All RCTs included in the selected reviews
were eligible if they included pain, function, or similar im-
provement measure as an outcome. Comparisons could be
between a treatment and placebo, usual care, “no treat-
ment,” or another treatment. Trials were excluded if they
did not present data in such a way that an effect size could be
calculated.
Quality Assessment
The list of criteria recommended by the CBRG Editorial Board
and the definition of the items are presented in Tables 1 and 2.
The quality assessment scores reported in the original Co-
chrane reviews were used. All items were scored “yes” if clearly
fulfilled, “no” if clearly not fulfilled or “don’t know” if it was
unclear from the paper if the item was fulfilled or not. Quality
assessment in all Cochrane reviews was done independently by
2 review authors and a consensus meeting was used to resolve
any disagreement between them. The first author (MvT) of the
Table 1. Cochrane Back Review Group Internal Validity
Checklist11
A Was the method of randomization adequate?
B Was the treatment allocation concealed?
C Were the groups similar at baseline regarding the most
important prognostic indicators?
D Was the patient blinded to the intervention?
E Was the care provider blinded to the intervention?
F Was the outcome assessor blinded to the intervention?
G Were co-interventions avoided or similar?
H Was the compliance acceptable in all groups?
I Was the drop-out rate described and acceptable?
J Was the timing of the outcome assessment in all groups similar?
K Did the analysis include an intention-to-treat analysis?
Table 2. Operationalization of the Criteria List
A A random (unpredictable) assignment sequence. Examples of
adequate methods are computer generated random No.
table and use of sealed opaque envelopes. Methods of
allocation using date of birth, date of admission, hospital
numbers, or alternation should not be regarded as
appropriate
B Assignment generated by an independent person not
responsible for determining the eligibility of the patients.
This person has no information about the persons
included in the trial and has no influence on the
assignment sequence or on the decision about eligibility
of the patient
C In order to receive a yes, groups have to be similar at
baseline regarding demographic factors, duration and
severity of complaints, percentage of patients with
neurologic symptoms, and value of main outcome
measure(s)
D The reviewer determines if enough information about the
blinding is given in order to score a yes
E The reviewer determines if enough information about the
blinding is given in order to score a yes
F The reviewer determines if enough information about the
blinding is given in order to score a yes
G Co-interventions should either be avoided in the trial design
or similar between the index and control groups
H The reviewer determines if the compliance to the
interventions is acceptable, based on the reported
intensity, duration, no. and frequency of sessions for both
the index intervention and control intervention(s)
I The No. participants who were included in the study but did
not complete the observation period or were not included
in the analysis must be described and reasons given. If
the percentage of withdrawals and drop-outs does not
exceed 20% for short-term follow-up and 30% for long-
term follow-up and does not lead to substantial bias a yes
is scored. (N.B. these percentages are arbitrary, not
supported by literature)
J Timing of outcome assessment should be identical for all
intervention groups and for all important outcome
assessments
K All randomized patients are reported/analyzed in the group
they were allocated to by randomization for the most
important moments of effect measurement (minus missing
values) irrespective of noncompliance and co-
interventions
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present article was involved in the quality assessment of 169 of
the 216 trials (78%); the last author (P.S.) in the assessment of
33 (15%).
Thirty-nine (18%) trials were included in more than one
Cochrane review. Five of these trials disagreed on the quality
score for one or more items.12–16 For these trials, the highest
quality rating was used.
Effect Sizes
Statistical data were collected for 1 outcome per trial. Means
and standard deviations were collected for continuous out-
comes (pain and function) and proportions for dichotomous
outcomes (e.g., proportion who improved). In cases where
more than 1 outcome was reported, we selected one using a
hierarchy: (1) short-term pain, (2) short-term function, (3)
long-term pain, (4) long-term function, (5) number of patients
improved in the short-term, (6) number of patients improved in
the long-term. Short-term was defined as closest to 6 weeks and
long-term as closest to 1 year. If a trial did not report any of
these outcomes, we did not include it. For trials that reported a
mean outcome but no standard deviation, we estimated the
Figure 1. Flow chart of trial se-
lection.
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standard deviation by taking the mean standard deviation,
weighted by the relevant treatment group’s sample size, across all
other trials that reported standard deviations for that outcome.17
Effect sizes were assessed because they convert different
scales into the same metric, so that they can be compared. Effect
sizes for continuous outcomes were calculated by dividing the
difference between the follow-up means of the 2 intervention
groups by the pooled follow-up standard deviations of the 2
intervention groups.18 Effect sizes for dichotomous outcomes
were calculated by using the Kraemer and Andrews estima-
tor,19 which uses the inverse normal cumulative distribution
function to transform from a dichotomous to a continuous
scale. We performed analyses using both the actual (either pos-
itive or negative) and the absolute (negative transformed to pos-
itive) value of the effect size. The difference between results using
either effect size was small, since relatively few trials reported neg-
ative effect sizes (only 15% of placebo controlled trials). Results
reported are for the absolute value of the effect size.
We included all trials in the analysis. We also ran each anal-
ysis separately for the intervention versus placebo/usual care
trials and the intervention versus intervention trials. In the case
of a multi-intervention trial, we only used 2 intervention arms,
or 1 comparison, in the analysis to avoid double counting. We
selected the comparison with the largest absolute effect size.
Figure 2. Difference in effect
sizes on studies based on quality
criteria.
Figure 3. Difference in effect
sizes for studies meeting or ex-
ceeding differing sum scores of
the criteria scored Yes.
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Statistical Analysis
The difference of effect sizes between studies with the quality
item scored yes and those with the quality item scored “not
yes” (no or don’t know) was used as a measure of bias associ-
ated with that quality item. The difference was estimated using
meta-regression.20 A meta-regression was conducted sepa-
rately for each quality item. The coefficient from each regres-
sion estimates the difference in effect sizes between studies with
the quality item scored yes versus those in which it is scored not
yes. A negative coefficient indicates that studies with the quality
item scored yes have smaller effect sizes than those that scored
not yes. All analyses were conducted in Stata 9.2.21
A sum score was calculated by adding the quality items that
were scored yes. The difference in effect sizes of studies above
and below all possible thresholds of 3 or more positive scores
(i.e., 4 or more vs. less than 4; 5 or more vs. less than 5; etc.) was
compared using the methods outlined above. We also per-
formed our analyses by intervention type. Each intervention
type that had 10 or more trials that could be assessed was
included in this analysis. We conducted a meta-regression for
each threshold score. Each meta-regression was a fully-
interacted model, containing a main effect for having the
threshold or higher number of quality items versus not, main
effects for each intervention type, and the interactions between
the threshold and each intervention. We report estimates for
those interventions that had at least 1 study that met the thresh-
old and 1 study that did not.
Results
Of the 15 Cochrane reviews22–36 on nonsurgical treat-
ment for nonspecific low back pain, 267 trials were eli-
gible for inclusion (Figure 1). Of these, 36 were excluded
because they did not provide sufficient data to calculate
an effect size. Four articles were in languages we could
not read, 1 did not have a primary outcome and 1 did not
report on a comparison of interest. We were unable to
obtain 9 articles. Thus, 216 trials were included in our
analysis: 122 where the back pain treatment was com-
pared to placebo or usual care and 128 trials where the
treatment was compared to another back-pain treatment
(which add up to more than 216 because some trials
compared more than 1 intervention to placebo or usual
care). Of these 216 trials, 139 (64%) reported short-term
pain outcomes, 14 (6%) reported short-term function
outcomes, 12 (6%) reported long-term pain outcomes, 7
(3%) report long-term function outcomes, 42 (19%) re-
ported short-term improvement, and 2 (1%) reported
long-term improvement. Fifty-four trials reported data
on more than 1 comparison. The number of internal
validity quality criteria fulfilled ranged from 1 to 11,
with a mean of 5.6.
Figure 2 presents the difference in effect sizes between
studies scoring yes or not yes on each of the 11 quality
criteria. There were smaller effect sizes for studies scoring
yes compared to studies scoring not yes for 10 of the 11
criteria, and for 6 of the criteria, the absolute difference
in effect sizes was 0.10 or greater. The 95% confidence
interval of the difference in effect sizes crossed the null
value in each case.
Figure 3 presents the difference in effect sizes for stud-
ies meeting or exceeding a particular score (threshold).
For each threshold, studies scoring above the threshold
had smaller effect sizes than studies scoring below the
threshold. The difference in effect sizes between trials
with higher and lower scores is 0.20 for thresholds of 5
and 6 and the 95% confidence intervals of these thresh-
olds do not cross the null value.
Table 3 presents the results of the meta-regression
analysis. It includes all interventions for which there
were at least 10 trials (except bed rest, which was fre-
quently the comparison group for trials of an active ther-
apy; and multidisciplinary treatment, which was too het-
erogeneous to classify as a therapy), and all thresholds.
As expected, there is variability in the difference in effect
sizes with the smaller sample sizes in each comparison.
However, this variability does not reflect chance. For 38
of the 56 comparisons where there was at least 1 study
scoring above and below the threshold, higher quality
studies had a smaller estimated effect size than lower
quality studies, compared to 17 times where the opposite
was observed (sign test, P  0.006). In comparisons
where there were at least 25% of the studies scoring
above or below the threshold, 19 of 21 higher quality
Table 3. Meta-Regression Analysis of Sum Score Association With Differences in Effect Sizes (DES) By Intervention
Intervention
Acupuncture Back School Behavior Therapy Exercise Therapy
Sum Score Yes No DES* 95% CI Yes No DES* 95% CI Yes No DES* 95% CI Yes No DES* 95% CI
2 vs. 2 24 1 0.88 (1.98, 0.23) 18 1 0.38 (0.72, 0.47) 15 1 0.33 (0.67, 1.32) 46 2 0.52 (1.28, 0.24)
3 vs. 3 20 5 0.40 (0.89, 0.09) 15 4 0.20 (0.76, 0.36) 13 3 0.18 (0.49, 0.85) 43 5 0.44 (0.97, 0.10)
4 vs. 4 17 8 0.29 (0.73, 0.15) 10 9 0.04 (0.48, 0.40) 12 4 0.12 (0.76, 0.52) 38 10 0.11 (0.50, 0.28)
5 vs. 5 15 10 0.29 (0.69, 0.10) 8 11 0.12 (0.54, 0.31) 10 6 0.33 (0.89, 0.23) 34 14 0.41 (0.74, 0.09)
6 vs. 6 13 12 0.20 (0.57, 0.17) 5 14 0.02 (0.42, 0.46) 5 11 0.15 (0.70, 0.40) 28 20 0.64 (0.92, 0.36)
7 vs. 7 10 15 0.13 (0.52, 0.26) 3 16 0.04 (0.60, 0.53) 2 14 0.27 (0.55, 1.09) 20 28 0.54 (0.82, 0.27)
8vs. 8 7 18 0.19 (0.63, 0.24) 2 17 0.01 (0.71, 0.69) 2 14 0.27 (0.57, 1.11) 10 38 0.33 (0.66, 0.00)
9 vs. 9 2 23 0.08 (0.66, 0.83) 0 19 — — 1 15 0.15 (1.21, 0.91) 6 42 0.32 (0.73, 0.09)
10 vs. 10 0 25 — — 0 19 — — 1 15 0.15 (1.21, 0.91) 2 46 0.30 (0.96, 0.35)
11 vs. 11 0 25 — — 0 19 — — 0 16 — — 1 47 0.52 (1.42, 0.38)
*Negative values mean studies scoring higher (lower risk of bias) have lower estimates of effect than studies scoring lower (higher risk of bias).
1689Evidence for Quality Sum Score • van Tulder et al
studies had estimated effect sizes that were smaller than
lower quality studies (sign test, P  0.0002). These data
support the conclusion that a summary score of these 11
items is associated with bias in effect size, regardless of
the intervention studied or threshold chosen.
Discussion
The 2 principal findings of our study are: that reports of
RCTs of low back pain treatments consistently report
smaller effect sizes if they fulfill most of the individual
items in the CBRG internal validity checklist; and at a
threshold of 5 or 6 fulfilled criteria, trials fulfilling more
criteria (low risk of bias) have effect sizes that are up to
0.20 lower than trials meeting fewer criteria (high risk of
bias). When 6 criteria were fulfilled, the average effect
size of trials meeting fewer than 6 criteria was 0.58,
whereas the average effect size of trials fulfilling more
than 6 criteria was 0.38, meaning that trials with a higher
risk of bias reported effect sizes that were, on average,
50% greater than estimates reported from trials with a
lower risk of bias. Our results are not substantially af-
fected by the contrast studied or the treatment assessed.
Prior studies of the effects of individual internal valid-
ity items are mixed. Juni et al reported a meta-analysis of
3 items—generation of the allocation sequence, conceal-
ment of treatment allocation, and double-blinding—that
were assessed in 4 methodologic studies that gauged
their relative importance in a large number of clinical
trials, while avoiding confounding by disease or by inter-
vention.37 In the original methodologic studies, these
items were mostly associated with smaller treatment ef-
fects (but not entirely so—in one methodologic study
double-blinding was associated with larger treatment ef-
fects5), but in about half of the instances, these differ-
ences were not statistically significant. In their pooled
analysis of the ratio of odds ratios, the generation of
allocation sequence had a pooled value of 0.81 (95% CI:
0.60–1.09), concealment of treatment allocation had a
pooled value of 0.70 (95% CI: 0.62–0.80), and double-
blinding had a pooled value of 0.86 (95% CI: 0.74–
0.99). Balk et al examined 24 quality criteria, assessing
276 trials in 4 clinical conditions, and found no criterion
that was associated with a statistically significantly dif-
ference in treatment effects.3 Eight of these 24 criteria
were identical or related to criteria in the CBRG internal
validity checklist. Our findings for individual items are
similar; none were associated with a statistically signifi-
cantly difference in treatment effect, although effect sizes
were consistently smaller if items were fulfilled.
Our results for the summary score are novel. Prior
attempts at assessing the effect of a summary scale
yielded no association between a scale developed by
Chalmers and coworkers,38 and a significant association
between higher scores on the Jadad scale and lower esti-
mates of treatment effects.5 Juni et al demonstrated in
one meta-analysis that the application of 25 different
scales yielded conflicting results.10 These data on vari-
ability contribute to many authorities’ lack of enthusi-
asm for scales, who advise instead an assessment of trials
according to individual quality components. However,
the problem remains of how to assess the validity of the
results of different trials when they vary on multiple in-
dividual quality criteria. This is particularly true in nar-
rative reviews of trials, where there is no meta-analytic
pooled estimate of effect to provide the basis for multiple
sensitivity analyses of the effect of individual compo-
nents on treatment estimates. Even with the use of only 3
quality criteria, there are 8 different potential combina-
tions of “yes” and “no” scores, making it a challenge to
assess the trade-offs in internal validity between trials
with different combinations of yes and no scores. With-
out an empirically-validated summary measure of inter-
nal validity, such assessments will be done on an ad hoc
basis, using decision-making rules that are idiosyncratic
and possibly unstated, or not done at all. The past prob-
lems with scales have been attributed to the heteroge-
neous nature of their criteria, with some scales including
criteria related to external validity, interpretation, or eth-
ical issues, and that many scales include items for which
there is little evidence that they are related to the internal
validity of the trial.10,37 It is possible that the more fa-
vorable results we found are because we restricted items
Table 3. Continued
Intervention
Manipulation Muscle Relaxation NSAIDs
Yes No DES* 95% CI Yes No DES* 95% CI Yes No DES* 95% CI
21 1 0.4 (0.70, 1.51) 25 0 — — 36 1 0.24 (0.80, 1.27)
20 2 0.37 (0.39, 1.14) 25 0 — — 36 1 0.24 (0.80, 1.27)
19 3 0.39 (1.11, 0.33) 24 1 0.30 (0.66, 1.25) 34 3 0.12 (0.45, 0.69)
16 6 0.42 (0.94, 0.11) 23 2 0.10 (0.62, 0.83) 26 11 0.19 (0.52, 0.14)
13 9 0.51 (0.93, 0.09) 20 5 0.04 (0.42, 0.49) 24 13 0.15 (0.46, 0.16)
9 13 0.23 (0.64, 0.18) 11 14 0.18 (0.21, 0.57) 13 24 0.02 (0.34, 0.29)
5 17 0.12 (0.58, 0.35) 4 21 0.34 (0.88, 0.20) 7 30 0.14 (0.27, 0.54)
1 21 0.46 (1.37, 0.44) 0 25 — — 3 34 0.02 (0.60, 0.55)
0 22 — — 0 25 — — 2 35 0.03 (0.66, 0.72)
0 22 — — 0 25 — — 0 37 — —
1690 Spine • Volume 34 • Number 16 • 2009
related only to internal validity, and that the items had
empirical evidence of content validity from their selec-
tion as part of the Delphi list process.
Our study has 2 primary limitations. The first is that
we relied on the internal validity assessment scores of the
authors of the original CBRG review. As such, we have
no measure of the inter-rater reliability of the scoring of
individual items across reviews. However, Verhagen et al
showed that the inter-rater reliability of 20 reviewers
using the criteria list was high,39 and Balk et al in their
study of similar criteria also reported high inter-rater
agreement. Furthermore, the first author of the present
article was involved in the quality assessment of 78% of
the trials. The second limitation is that all of the clinical
trials assessed patients with low back pain. Previous as-
sessments of the relationship between quality criteria or
scales and the estimate of treatment effects have been
critiqued if they were subject to potential confounding
by condition or by intervention. Our study included tri-
als of many different interventions, and our meta-
regression analyses support the validity of our findings
for interventions as disparate as pharmaceuticals, behav-
ioral therapies, and complementary and alternative med-
icine therapies. However, we cannot fully exclude the
possibility of confounding by condition, although we do
note that the items in the CBRG internal validity list seem
broadly applicable and not specific to back pain. These
items have indeed been used in systematic reviews of
other conditions.
In summary, we found evidence that a small number
of items in the CBRG internal validity checklist that are
fulfilled appears to be associated with biased treatment
effects. Studies fulfilling fewer than 5 or 6 of 11 items had
significantly higher estimates of treatment effects. Our
data support the use of a score, reached by adding the
number of i tems in this l i s t that are fulfil -
led, to indicate the internal validity of randomized trials
of treatments for patients with low back pain. We believe
that it’s likely that the CBRG internal validity list is also
useful for the assessment of trials in other conditions.
Key Points
● There is concern that studies of low method-
ologic quality may exaggerate the effectiveness of
treatments for low back pain.
● We assessed the relationship between the 11
items contained in the Cochrane Back Review
Group Internal Validity checklist and effect size in
randomized trials of interventions for back pain.
● Two hundred sixteen trials of 15 Cochrane re-
views were included in the analysis.
● The number of items fulfilled showed that trials
with higher scores consistently reported smaller ef-
fect sizes than trials with lower scores. At the
thresholds of 5 or 6 items fulfilled, the difference in
effect sizes was 0.20 in each case.
● The 11-item Internal Validity Checklist is asso-
ciated with effect size in randomized trials of inter-
ventions for back pain, and that our data support
the use of a sum score.
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